{
 "version": "https://jsonfeed.org/version/1.1",
 "title": "Mepa8",
 "home_page_url": "https://mepa8.com/",
 "feed_url": "https://mepa8.com/feed.json",
 "description": "Medicine, public health and EMS news, sourced every day.",
 "language": "en-US",
 "icon": "https://mepa8.com/assets/logo.png",
 "authors": [
  {
   "name": "Mepa8 Newsroom",
   "url": "https://mepa8.com/editorial-policy/#ai"
  }
 ],
 "items": [
  {
   "id": "https://mepa8.com/medicine/2026/10/21/hibsago-bepirovirsen-fda-approval-for-chronic-hepatitis-b/",
   "url": "https://mepa8.com/medicine/2026/10/21/hibsago-bepirovirsen-fda-approval-for-chronic-hepatitis-b/",
   "title": "FDA approves Hibsago, first antisense drug for chronic hepatitis B, with boxed warning",
   "summary": "In two placebo-controlled trials, 24% of patients on the drug met criteria to stop all hepatitis B therapy, and 19% still had the virus under control 24 weeks later, the FDA said.",
   "image": "https://mepa8.com/assets/img/hibsago-bepirovirsen-fda-approval-for-chronic-hepatitis-b-1600.jpg",
   "date_published": "2026-10-21T13:27:14-07:00",
   "date_modified": "2026-10-21T13:27:14-07:00",
   "tags": [
    "Medicine",
    "Hibsago",
    "bepirovirsen",
    "FDA approval hepatitis B",
    "chronic hepatitis B treatment",
    "antisense oligonucleotide hepatitis B"
   ],
   "authors": [
    {
     "name": "Mepa8 Newsroom"
    }
   ],
   "_mepa8": {
    "sources": [
     "https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment"
    ],
    "takeaways": [
     "The FDA approved Hibsago (bepirovirsen) injection on October 20, 2026, for chronic hepatitis B in certain adults without cirrhosis, used with existing antiviral therapy.",
     "The FDA calls it the first approved antisense oligonucleotide for chronic hepatitis B; the approval went to GSK plc.",
     "Across two placebo-controlled trials, 24% of Hibsago patients met the requirements to stop their existing hepatitis B medicine, compared with none on placebo.",
     "Hibsago carries a boxed warning for serious liver reactions and low platelet counts, plus warnings for worsening kidney function and inflammatory reactions such as vasculitis.",
     "For crews: patients on Hibsago receive it as an under-the-skin injection for up to 24 weeks and need regular blood tests during treatment, per the FDA release."
    ]
   }
  },
  {
   "id": "https://mepa8.com/ems/2026/10/21/bystander-cpr-rose-in-french-dispatcher-and-app-trial/",
   "url": "https://mepa8.com/ems/2026/10/21/bystander-cpr-rose-in-french-dispatcher-and-app-trial/",
   "title": "Dispatcher and volunteer-app package raised bystander CPR in French trial but not outcomes",
   "summary": "Bystander CPR before EMS arrival occurred in 70.9% of intervention patients versus 61.4% of controls, but the effect lost statistical significance once the authors adjusted for secular trends.",
   "image": "https://mepa8.com/assets/img/bystander-cpr-rose-in-french-dispatcher-and-app-trial-1600.jpg",
   "date_published": "2026-10-21T13:12:47-07:00",
   "date_modified": "2026-10-21T13:12:47-07:00",
   "tags": [
    "EMS",
    "bystander CPR trial France",
    "dispatcher-assisted CPR",
    "telephone CPR stepped-wedge trial",
    "out-of-hospital cardiac arrest bystander CPR",
    "volunteer responder app cardiac arrest"
   ],
   "authors": [
    {
     "name": "Mepa8 Newsroom"
    }
   ],
   "_mepa8": {
    "sources": [
     "https://pubmed.ncbi.nlm.nih.gov/42901186/"
    ],
    "takeaways": [
     "A stepped-wedge trial in The Lancet Public Health linked a package of dispatcher training, a volunteer smartphone app and agency feedback to more bystander CPR across 14 French EMS agencies.",
     "Bystander CPR before EMS arrival occurred in 61.4% of control patients and 70.9% of intervention patients, with an adjusted odds ratio of 1.54.",
     "The effect was no longer statistically significant after adjustment for cluster-specific secular trends or baseline characteristics, and the authors reported it did not improve clinical outcomes.",
     "The dispatcher protocol targeted recognition of cardiac arrest within 60 s of call pick-up and first compression within a further 60 s, using scripted compression-only instructions.",
     "For crews: the abstract reports no intervention-related adverse events and gives no survival figures; the outcome measures behind the clinical-outcome statement are not described in the record."
    ]
   }
  },
  {
   "id": "https://mepa8.com/recalls/2026/10/21/safeguard-battle-bandage-ifak-kit-recall-fda-class-ii/",
   "url": "https://mepa8.com/recalls/2026/10/21/safeguard-battle-bandage-ifak-kit-recall-fda-class-ii/",
   "title": "FDA posts Class II recall of Safeguard Battle Bandage and IFAK trauma kits, 46,881 units",
   "summary": "The FDA record says the compression bandage may be degraded and could introduce foreign material into a wound, with distribution across the United States and abroad.",
   "image": "https://mepa8.com/assets/img/safeguard-battle-bandage-ifak-kit-recall-fda-class-ii-1600.jpg",
   "date_published": "2026-10-21T12:57:57-07:00",
   "date_modified": "2026-10-21T12:57:57-07:00",
   "tags": [
    "Drugs & FDA",
    "Safeguard Battle Bandage recall",
    "Safeguard IFAK recall",
    "Battle Bandage 32-700 recall",
    "FDA Class II recall IFAK",
    "Z-0081-2027"
   ],
   "authors": [
    {
     "name": "Mepa8 Newsroom"
    }
   ],
   "_mepa8": {
    "sources": [
     "https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-0081-2027%22"
    ],
    "takeaways": [
     "Safeguard US Operating LLC of Huntersville, North Carolina, is recalling its Battle Bandage (REF 32-700) and the IFAK, trauma, and bleeding-control kits listed under FDA recall number Z-0081-2027.",
     "The FDA classified the recall as Class II; the record lists 46,881 units and a status of Ongoing.",
     "The stated reason is that the compression bandage may be degraded and may introduce foreign material into a wound, which the record links to wound exploration and irrigation, scar tissue, and infection.",
     "The firm started the recall by letter on September 2, 2026; the FDA posted the enforcement report on October 14, 2026, and distribution was US nationwide plus the countries coded BRA, BEL, SGP and AUS.",
     "For crews: the record identifies affected stock by REF number, UDI-DI and lot, with Battle Bandage lots carrying the PBO prefix under UDI-DI M68932700070 and separate lot lists for each kit REF."
    ]
   }
  },
  {
   "id": "https://mepa8.com/ems/2026/10/13/heartsine-aed-recalls-samaritan-pad/",
   "url": "https://mepa8.com/ems/2026/10/13/heartsine-aed-recalls-samaritan-pad/",
   "title": "HeartSine's fourth AED recall since mid-2025: what samaritan PAD owners need to check",
   "summary": "The newest, reported by the FDA on Oct. 7, covers 31,834 public-access defibrillators that shipped without a supplement adding a check every three months.",
   "image": "https://mepa8.com/assets/img/aed-lead-1600.jpg",
   "date_published": "2026-10-13T09:00:00-07:00",
   "date_modified": "2026-10-13T09:00:00-07:00",
   "tags": [
    "EMS",
    "HeartSine recall",
    "samaritan PAD recall",
    "AED recall 2026",
    "FDA device recall",
    "public access defibrillator"
   ],
   "authors": [
    {
     "name": "Ryan Bolden"
    }
   ],
   "_mepa8": {
    "sources": [
     "https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-3270-2026%22",
     "https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-3120-2026%22",
     "https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-0288-2026%22",
     "https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-2174-2025%22"
    ],
    "takeaways": []
   }
  }
 ]
}